Bonus Oct 18, 1999 Nov 05, 1999 Oct 07, 1999 Bonus Ratio: 2 share(s) for every 1 shares held Rights Feb 03, 1995 Mar 02, 1995 May 03, 1995 Rights ratio: 4 share for every 50 held at a price of Rs ...

Cipla Limited is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and ...

208. During the year, the Generics Business Undertaking of the Company was transferred to Cipla Pharma and Life Sciences Limited (CPLS), wholly owned subsidiary, on a slump sale basis as a going ...

For the quarter, net profit soared 49% on-year to ₹1,570 crore, on the back of higher revenue and better operating efficiency.

Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is ...

The Capital Structure page of Cipla Ltd. presents the Authorized Capital, Issued Capital, and Paid-Up Equity Capital of the company over the period.

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Cipla is currently headquartered in Mumbai and has extended its presence to more than 80 countries. Cipla offers an array of more than 1500 therapeutic products that echo its guiding purpose and ...

Drug major Cipla Ltd is the latest company to declare its schedule for the release of its earnings report for the fourth quarter of the financial year 2024-25. The pharmaceutical company informed this ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Nomura India maintained its 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. Cipla anticipates ...

Sun Pharma is projected to lead in PAT growth at 28% YoY, while Cipla might see a 5% YoY decline, according to Centrum ...